Contact
Please use this form to send email to PR contact of this press release:
WPD Pharmaceuticals’ WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials
TO:
Please use this form to send email to PR contact of this press release:
WPD Pharmaceuticals’ WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials
TO: